Genmab — December 2017
-
Munk says
** Genmab expects its expenses to grow 40-50 pct next year (Full Story)
** Sydbank analyst Soren Lontoft highlights the competition from rival Bluebird BLUE.O as the reason for the share drop
** "I think the investors react to the fact that there are some of these competitors who steal the limelight with some really strong results"
** Bluebird experimental gene-modifying immunotherapy drug, bb2121, co-developed with Celgene CELG.O, received positive responses in early stage myeloma s -
study, the firm said during the ASH meeting (
-
Ja, sådan forstår jeg det også
-
...men det er jo ikke ligefrem den fede meddelelse, når man er lykkededs med at rapportere vækst-stop i et af de mest vellykkede cancer launches nogensinde
-
Nej - men tallet kan udledes af det, der blev sagt
-
ja det er det med rapporteringer igen igen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind